1. Home
  2. EEX vs REPL Comparison

EEX vs REPL Comparison

Compare EEX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Emerald Holding Inc.

EEX

Emerald Holding Inc.

N/A

Current Price

$4.94

Market Cap

880.2M

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$8.04

Market Cap

781.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EEX
REPL
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
880.2M
781.3M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
EEX
REPL
Price
$4.94
$8.04
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$7.70
$12.00
AVG Volume (30 Days)
115.2K
1.2M
Earning Date
10-31-2025
02-11-2026
Dividend Yield
1.22%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$437,500,000.00
N/A
Revenue This Year
$16.88
N/A
Revenue Next Year
$6.97
N/A
P/E Ratio
$241.38
N/A
Revenue Growth
11.18
N/A
52 Week Low
$3.22
$2.68
52 Week High
$5.45
$14.80

Technical Indicators

Market Signals
Indicator
EEX
REPL
Relative Strength Index (RSI) 57.13 34.70
Support Level $4.42 $7.87
Resistance Level $5.09 $9.41
Average True Range (ATR) 0.22 0.48
MACD 0.02 -0.18
Stochastic Oscillator 65.88 7.50

Price Performance

Historical Comparison
EEX
REPL

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: